EcoDrugPlus

Microtubule Associated Protein Tau

Ensembl ID : ENSOCUG00000011386
Gene Symbol: MAPT
3 Cross references
255 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSOCUG00000013692
Gene Symbol: MAPK1
2 Cross references
213 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSOCUG00000010663
Gene Symbol: MAPK10
2 Cross references
147 Possible Orthologues:

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSOCUG00000013716
Gene Symbol: MAPK3
2 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSOCUG00000002873
Gene Symbol: MAPK8
3 Cross references
293 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSOCUG00000015542
Gene Symbol: MAPK9
3 Cross references
217 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSOCUG00000008782
Gene Symbol: MAP2K1
2 Cross references
209 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSOCUG00000009155
Gene Symbol: MAP3K1
2 Cross references
160 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSOCUG00000013657
Gene Symbol: MAP3K10
2 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSOCUG00000013282
Gene Symbol: MAP3K11
3 Cross references
183 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSOCUG00000005689
Gene Symbol: MAP3K12
3 Cross references
254 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSOCUG00000005035
Gene Symbol: MAP3K13
3 Cross references
198 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).